SCHEMBL30120728

SCHEMBL30120728

CC(C)n1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2ccc(F)c(C(F)(F)F)c2)c2c(N)ncnc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK3 Q9NZJ5 14/20 0.58
RIPK1 Q13546 10/20 0.58
EIF2AK2 P19525 6/20 0.58
EIF2AK1 Q9BQI3 6/20 0.58
CYP3A4 P08684 4/20 0.58
CYP2C9 P11712 3/20 0.58
EIF2AK4 Q9P2K8 2/20 0.58
CYP2C8 P10632 2/20 0.58
CYP2D6 P10635 2/20 0.58
NTRK1 P04629 2/20 0.47
LCK P06239 2/20 0.47
YES1 P07947 2/20 0.47
RET P07949 2/20 0.47
KIT P10721 2/20 0.47
AXL P30530 2/20 0.47
MAP3K9 P80192 2/20 0.47
MAP3K10 Q02779 2/20 0.47
MERTK Q12866 2/20 0.47
PTK6 Q13882 2/20 0.47
NTRK3 Q16288 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24650630 1.00 EIF2AK3 (0.58) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL868357 0.90 EIF2AK3 (0.70) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL30120764 0.86 RIPK1 (0.52) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL24650671 0.86 RIPK1 (0.52) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL24650624 0.81 RIPK1 (0.54) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL30486107 0.81 RIPK1 (0.54) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL24651094 0.80 RIPK1 (0.52) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL30120724 0.80 RIPK1 (0.52) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL24650623 0.79 RIPK1 (0.49) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4
SCHEMBL30120757 0.79 RIPK1 (0.49) EIF2AK3RIPK1EIF2AK2EIF2AK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382488-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-11-21 US disclosed
WO-2022212326-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382488-A1 NEK7 INHIBITORS NEK7, NEK11, NEK2 EIF2AK3 2387/4885RIPK1 537/4885EIF2AK2 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.